{"id":4628,"date":"2025-10-30T12:02:59","date_gmt":"2025-10-30T10:02:59","guid":{"rendered":"https:\/\/integragen.com\/?p=4628"},"modified":"2025-10-30T12:02:59","modified_gmt":"2025-10-30T10:02:59","slug":"charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025","status":"publish","type":"post","link":"https:\/\/integragen.com\/en\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/","title":{"rendered":"OPERATING EXPENSES DOWN 20% AND CASH POSITION AT \u20ac1.7 M AT JUNE 30, 2025"},"content":{"rendered":"<p><\/p>\n\n\n\n<p><strong>Half-year results 2025<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Operating expenses down 20%<\/li>\n\n\n\n<li>Cash position of \u20ac1.7 million at June 30, 2025<\/li>\n\n\n\n<li>Focus on operational execution and development of clinical\/pharmaceutical activities<\/li>\n\n\n\n<li>supported by CLIA\/CAP certification<\/li>\n<\/ul>\n\n\n\n<p><strong>EVRY, FRANCE, THURSDAY OCTOBER 29, 2025, 5:45 PM - IntegraGen (FR0010908723 - ALINT - PEA PME eligible)<\/strong>,<br>a company specializing in the genomics of cancer and rare genetic diseases, which carries out analyses of<br>and interpretable data for academic and private laboratories, today announces<br>its unaudited results for the first half of 2025, the accounts having been approved by the Board<br>of October 16, 2025.<\/p>\n\n\n\n<p><strong>FINANCIAL INFORMATION<\/strong><\/p>\n\n\n\n<p><strong>Simplified income statement<br>In thousands of euros<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>June 30-2025<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>June 30-2025<\/strong><\/td><\/tr><tr><td><strong>Revenue<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>2 564<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>4 570<\/strong><\/td><\/tr><tr><td>Of which SeqOIA revenues<\/td><td class=\"has-text-align-center\" data-align=\"center\">0<\/td><td class=\"has-text-align-center\" data-align=\"center\">727<\/td><\/tr><tr><td>Operating subsidies and other income<\/td><td class=\"has-text-align-center\" data-align=\"center\">185<\/td><td class=\"has-text-align-center\" data-align=\"center\">269<\/td><\/tr><tr><td><strong>Total Products<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>2 749<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>4 839<\/strong><\/td><\/tr><tr><td>Operating expenses<\/td><td class=\"has-text-align-center\" data-align=\"center\">4 181<\/td><td class=\"has-text-align-center\" data-align=\"center\">5 196<\/td><\/tr><tr><td><strong>Gross operating surplus<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>-1 432<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>-357<\/strong><\/td><\/tr><tr><td>Depreciation and amortization<br>provisions<\/td><td class=\"has-text-align-center\" data-align=\"center\">35<\/td><td class=\"has-text-align-center\" data-align=\"center\">53<\/td><\/tr><tr><td>Operating income<\/td><td class=\"has-text-align-center\" data-align=\"center\">-1 467<\/td><td class=\"has-text-align-center\" data-align=\"center\">-410<\/td><\/tr><tr><td>Financial result<\/td><td class=\"has-text-align-center\" data-align=\"center\">21<\/td><td class=\"has-text-align-center\" data-align=\"center\">40<\/td><\/tr><tr><td>Net exceptional income<\/td><td class=\"has-text-align-center\" data-align=\"center\">0<\/td><td class=\"has-text-align-center\" data-align=\"center\">219<\/td><\/tr><tr><td>Tax credits<\/td><td class=\"has-text-align-center\" data-align=\"center\">39<\/td><td class=\"has-text-align-center\" data-align=\"center\">36<\/td><\/tr><tr><td><strong>Net income<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>-1 407<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>-115<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Revenues for the first half of 2025 amounted to \u20ac2,749,000.<\/strong>down <strong>43%<\/strong> in relation to the first<br>half-year 2024. In the first quarter of 2024, there were 727 k\u20ac of non-recurring income related to the<br>leftover from the SeqOIA contract. Adjusted for this impact, the decline in sales was 33%.<\/p>\n\n\n\n<p>Operating expenses came to \u20ac4,181k, down 201TP3Q on the first half.<br>2024, reflecting a reduction in raw materials consumption, a reduction in the weight<br>9%, and a reduction in external expenses of 22 % linked to the implementation of a<br>savings.<\/p>\n\n\n\n<p><strong>Earnings before interest, tax, depreciation and amortization (EBITDA) came to \u20ac1,432,000.<\/strong><br>compared with -357 K\u20ac in the first half of 2024. After taking into account financial results, <strong>the result<br>net loss was -1,407 K\u20ac compared with -115 K\u20ac in the first half of 2024.<\/strong><\/p>\n\n\n\n<p><strong>B\u00e9reng\u00e8re G\u00e9nin, Managing Director, IntegraGen<\/strong>declares: \"The first half of 2025 has been<br>marked by the continued adaptation of IntegraGen following the discontinuation of services for the GCS<br>SeqOIA and a difficult environment for academic and hospital research.<br>We have implemented operational efficiency and cost-cutting measures, while at the same time<br>adapting our operations to the needs of our industrial customers. Thanks to our<br>CLIA\/CAP, IntegraGen is now in a position to support the clinical development of its products.<br>pharmaceutical partners.<\/p>\n\n\n\n<p><strong>Simplified liabilities<br>In thousands of euros<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><\/td><td class=\"has-text-align-center\" data-align=\"center\">June 30-2025<\/td><td class=\"has-text-align-center\" data-align=\"center\">31-Dec-2024<\/td><\/tr><tr><td><strong>Shareholders' equity<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>348<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>1 755<\/strong><\/td><\/tr><tr><td>Provisions for contingencies and charges<\/td><td class=\"has-text-align-center\" data-align=\"center\">10<\/td><td class=\"has-text-align-center\" data-align=\"center\">12<\/td><\/tr><tr><td>Financial liabilities<\/td><td class=\"has-text-align-center\" data-align=\"center\">417<\/td><td class=\"has-text-align-center\" data-align=\"center\">643<\/td><\/tr><tr><td>Trade payables<\/td><td class=\"has-text-align-center\" data-align=\"center\">942<\/td><td class=\"has-text-align-center\" data-align=\"center\">913<\/td><\/tr><tr><td>Tax and social security liabilities<\/td><td class=\"has-text-align-center\" data-align=\"center\">913<\/td><td class=\"has-text-align-center\" data-align=\"center\">1025<\/td><\/tr><tr><td>Other liabilities<\/td><td class=\"has-text-align-center\" data-align=\"center\">139<\/td><td class=\"has-text-align-center\" data-align=\"center\">34<\/td><\/tr><tr><td>Deferred income<\/td><td class=\"has-text-align-center\" data-align=\"center\">844<\/td><td class=\"has-text-align-center\" data-align=\"center\">1 133<\/td><\/tr><tr><td>Cumulative translation adjustment<\/td><td class=\"has-text-align-center\" data-align=\"center\"><\/td><td class=\"has-text-align-center\" data-align=\"center\"><\/td><\/tr><tr><td><strong>Total liabilities<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>3 613<\/strong><\/td><td class=\"has-text-align-center\" data-align=\"center\"><strong>5 515<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Cash and cash equivalents at June 30, 2025 stood at \u20ac1,721,000.<\/strong>179 K\u20ac lower than at the end of December 2024. This position takes into account the partial repayment of 600 K\u20ac on the 1 M\u20ac loan granted to<br>OncoDNA in August 2023, with the remaining \u20ac400,000 to be repaid in the second half of 2025.<\/p>\n\n\n\n<p>At this cash level and based on the current rate of consumption, the Company estimates that its<br>free cash flow allows us to continue our business until between the end of 2025 and the end of 2025<br>and the first quarter of 2026, with no new external financing.<\/p>\n\n\n\n<p><strong>About IntegraGen<\/strong><br>IntegraGen specializes in the genomics of cancer and genetic diseases. Backed by highly experienced, qualified teams, IntegraGen is a major player in DNA sequencing services and genomic data interpretation software. The company manages one of the largest NGS laboratories in France and operates for leading research institutes. IntegraGen harnesses the potential of high-throughput sequencing to offer patients the promise of precision medicine. IntegraGen has over 40 employees and generated revenues of 8.5 million euros in<br>2024.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"332\" height=\"152\" src=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CliaCap.png\" alt=\"\" class=\"wp-image-2896\" srcset=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CliaCap.png 332w, https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CliaCap-300x137.png 300w, https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CliaCap-18x8.png 18w\" sizes=\"auto, (max-width: 332px) 100vw, 332px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"187\" height=\"81\" src=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CAP-accredited.png\" alt=\"\" class=\"wp-image-2898\" srcset=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CAP-accredited.png 187w, https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/CAP-accredited-18x8.png 18w\" sizes=\"auto, (max-width: 187px) 100vw, 187px\" \/><\/figure>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p><strong>CONTACTS<\/strong><\/p>\n\n\n\n<p><strong>IntegraGen<\/strong><br>B\u00e9reng\u00e8re G\u00e9nin,<br>General Manager<\/p>\n\n\n\n<p>contact@integragen.com<br>Phone: +33 (0)1 60 91 09 00<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"273\" height=\"133\" src=\"https:\/\/integragen.com\/wp-content\/uploads\/2025\/10\/Alint.png\" alt=\"\" class=\"wp-image-4608\" srcset=\"https:\/\/integragen.com\/wp-content\/uploads\/2025\/10\/Alint.png 273w, https:\/\/integragen.com\/wp-content\/uploads\/2025\/10\/Alint-18x9.png 18w\" sizes=\"auto, (max-width: 273px) 100vw, 273px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p><\/p>\n\n\n\n<p><strong>NEWCAP<br>Investor Relations<\/strong><br>Louis-Victor DELOUVRIER<\/p>\n\n\n\n<p>integragen@newcap.eu<br>Phone: +33 (0)1 44 71 98 53<\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>R\u00e9sultats du 1er semestre 2025 EVRY, FRANCE, JEUDI 29 OCTOBRE 2025, 17H45 &#8211; IntegraGen (FR0010908723 \u2013 ALINT \u2013 Eligible PEA PME),une soci\u00e9t\u00e9 sp\u00e9cialis\u00e9e dans la g\u00e9nomique du cancer et des maladies g\u00e9n\u00e9tiques rares, qui r\u00e9alise des analysesg\u00e9nomiques et de donn\u00e9es, interpr\u00e9tables pour des laboratoires acad\u00e9miques et priv\u00e9s, annonce aujourd&rsquo;huises r\u00e9sultats non-audit\u00e9s du premier semestre 2025,&#8230;<\/p>","protected":false},"author":2,"featured_media":140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ca_portfolio_gallery_project_year":"","ca_portfolio_gallery_client":"","ca_portfolio_gallery_skills":"","ca_portfolio_gallery_url":"","ca_portfolio_gallery_images":"","_eb_attr":"","footnotes":""},"categories":[6,1],"tags":[],"class_list":["post-4628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse","category-toutes-les-categories"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CHARGES D&#039;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025<\/title>\n<meta name=\"description\" content=\"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/integragen.com\/en\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CHARGES D&#039;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025\" \/>\n<meta property=\"og:description\" content=\"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle\" \/>\n<meta property=\"og:url\" content=\"https:\/\/integragen.com\/en\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"IntegraGen\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T10:02:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"268\" \/>\n\t<meta property=\"og:image:height\" content=\"158\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"marine Deruy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"marine Deruy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/\"},\"author\":{\"name\":\"marine Deruy\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/person\\\/f7984826e661ce0b8d186cd690160607\"},\"headline\":\"CHARGES D&rsquo;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025\",\"datePublished\":\"2025-10-30T10:02:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/\"},\"wordCount\":703,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/chiffre-affaires-integragen-2021-268x158-1.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\",\"Toutes les Cat\u00e9gories\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/\",\"name\":\"CHARGES D'EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/chiffre-affaires-integragen-2021-268x158-1.jpg\",\"datePublished\":\"2025-10-30T10:02:59+00:00\",\"description\":\"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/chiffre-affaires-integragen-2021-268x158-1.jpg\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/chiffre-affaires-integragen-2021-268x158-1.jpg\",\"width\":268,\"height\":158},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/integragen.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Toutes les Cat\u00e9gories\",\"item\":\"https:\\\/\\\/integragen.com\\\/toutes-les-categories\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CHARGES D&rsquo;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#website\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"name\":\"IntegraGen - Clinical Genomic Experts\",\"description\":\"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CRO\",\"publisher\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\"},\"alternateName\":\"IntegraGen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/integragen.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#organization\",\"name\":\"IntegraGen\",\"url\":\"https:\\\/\\\/integragen.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"contentUrl\":\"https:\\\/\\\/integragen.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/Logo_IntegraGen_OncoDNA.png\",\"width\":2478,\"height\":684,\"caption\":\"IntegraGen\"},\"image\":{\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/integragen\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/integragen.com\\\/#\\\/schema\\\/person\\\/f7984826e661ce0b8d186cd690160607\",\"name\":\"marine Deruy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g\",\"caption\":\"marine Deruy\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CHARGES D'EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025","description":"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/integragen.com\/en\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/","og_locale":"en_US","og_type":"article","og_title":"CHARGES D'EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025","og_description":"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle","og_url":"https:\/\/integragen.com\/en\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/","og_site_name":"IntegraGen","article_published_time":"2025-10-30T10:02:59+00:00","og_image":[{"width":268,"height":158,"url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg","type":"image\/jpeg"}],"author":"marine Deruy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"marine Deruy","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#article","isPartOf":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/"},"author":{"name":"marine Deruy","@id":"https:\/\/integragen.com\/#\/schema\/person\/f7984826e661ce0b8d186cd690160607"},"headline":"CHARGES D&rsquo;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025","datePublished":"2025-10-30T10:02:59+00:00","mainEntityOfPage":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/"},"wordCount":703,"commentCount":0,"publisher":{"@id":"https:\/\/integragen.com\/#organization"},"image":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg","articleSection":["Communiqu\u00e9s de presse","Toutes les Cat\u00e9gories"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/","url":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/","name":"CHARGES D'EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025","isPartOf":{"@id":"https:\/\/integragen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#primaryimage"},"image":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg","datePublished":"2025-10-30T10:02:59+00:00","description":"R\u00e9sultats du 1er semestre 2025 Charges d\u2019exploitation en baisse de 20% Position de tr\u00e9sorerie \u00e0 1,7 M\u20ac au 30 juin 2025 Cap sur l\u2019ex\u00e9cution op\u00e9rationnelle","breadcrumb":{"@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#primaryimage","url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/07\/chiffre-affaires-integragen-2021-268x158-1.jpg","width":268,"height":158},{"@type":"BreadcrumbList","@id":"https:\/\/integragen.com\/toutes-les-categories\/charges-dexploitation-en-baisse-de-20-et-position-de-tresorerie-a-17-me-au-30-juin-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/integragen.com\/"},{"@type":"ListItem","position":2,"name":"Toutes les Cat\u00e9gories","item":"https:\/\/integragen.com\/toutes-les-categories\/"},{"@type":"ListItem","position":3,"name":"CHARGES D&rsquo;EXPLOITATION EN BAISSE DE 20% ET POSITION DE TR\u00c9SORERIE \u00c0 1,7 M\u20ac AU 30 JUIN 2025"}]},{"@type":"WebSite","@id":"https:\/\/integragen.com\/#website","url":"https:\/\/integragen.com\/","name":"IntegraGen - Clinical Genomic Experts","description":"NGS Sequencing &amp; Bioinformatics for Pharma, Biotech &amp; CROs","publisher":{"@id":"https:\/\/integragen.com\/#organization"},"alternateName":"IntegraGen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/integragen.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/integragen.com\/#organization","name":"IntegraGen","url":"https:\/\/integragen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/","url":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","contentUrl":"https:\/\/integragen.com\/wp-content\/uploads\/2024\/09\/Logo_IntegraGen_OncoDNA.png","width":2478,"height":684,"caption":"IntegraGen"},"image":{"@id":"https:\/\/integragen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/integragen\/"]},{"@type":"Person","@id":"https:\/\/integragen.com\/#\/schema\/person\/f7984826e661ce0b8d186cd690160607","name":"marine Deruy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5685106104a4c5e6743b91f64c795a73a59ee61d6ed874b92a492380bb90952c?s=96&d=mm&r=g","caption":"marine Deruy"}}]}},"_links":{"self":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/4628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/comments?post=4628"}],"version-history":[{"count":2,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/4628\/revisions"}],"predecessor-version":[{"id":4631,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/posts\/4628\/revisions\/4631"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/media\/140"}],"wp:attachment":[{"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/media?parent=4628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/categories?post=4628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/integragen.com\/en\/wp-json\/wp\/v2\/tags?post=4628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}